Brian McKelligon - Sep 7, 2022 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
President/CEO
Signature
/s/ Brian McKelligon
Stock symbol
AKYA
Transactions as of
Sep 7, 2022
Transactions value $
-$62,655
Form type
4
Date filed
9/9/2022, 04:00 PM
Previous filing
Jun 17, 2022
Next filing
Dec 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Options Exercise $1.52K +5K +6.25% $0.30* 85K Sep 7, 2022 Direct
transaction AKYA Common Stock Sale -$64.2K -5K -5.88% $12.83 80K Sep 7, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Employee Stock Option (Right to Buy) Options Exercise $0 -5K -1.44% $0.00 343K Sep 7, 2022 Common Stock 5K $0.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian M. McKelligon dated May 16, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at pri ces ranging from $12.12 to $12.99, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F3 The option, representing a right to purchase a total of 353,129 shares, became exercisable as follows: one -fourth of the shares vested on July 14, 2018 with the remaining shares vesting in 36 equal monthly installments beginning on July 14, 2018, subject to reporting person's continuous employment.